Introduction

Successful shared care arrangements enable the combination of the best of both primary and secondary care for the benefit of the patient. They allow the seamless transfer of patient treatment from the secondary care sector to general practice. While protocols and guidelines may be useful, they in themselves do not constitute an adequate basis for shared care operations.

This Effective Shared Care Agreement Toolkit (denosumab [Prolia®]) is designed to assist healthcare professionals in the development of their own shared care agreements to support locally agreed policy on the prescribing of denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. In particular, it suggests ways in which responsibilities can be shared between the secondary care specialist and general practitioner (GP) / primary care prescriber. The Toolkit is intended to act as a flexible template that enables users to consider suggested content and tailor it to local circumstances and requirements.

Please note that the Effective Shared Care Agreement Toolkit is not a recommendation to prescribe denosumab. The decision to prescribe denosumab is the responsibility of the respective local healthcare organisation and the Toolkit should only be used after the local decision to prescribe denosumab has been taken.

To support your local decision-making you may wish to refer to:

Further support materials are available from the manufacturer:

As of today's date, the Midlands Therapeutics Review and Advisory Committee (MTRAC) has yet to consider denosumab.

Enter the Effective Shared Care Agreement Toolkit (denosumab [Prolia®]).

Keele University is not responsible for the content of any linked site or manufacturer's material. Listing and linking should not be taken as an endorsement of any kind and we accept no liability in respect of the content.